Navamedic ASA: Broad launch for Eroxon® in Sweden today

OSLO, Norway, May 6, 2024 /PRNewswire/ — Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies has launched Eroxon® in Sweden. Eroxon® is clinically proven and considered a breakthrough in treatment of erectile dysfunction for men and will be the first non-prescription treatment for erectile dysfunction in the Swedish market.

Eroxon® was launched in Norway in February 2024 and has been very well received by Norwegian consumers. After only two weeks in the market, it was the bestseller at an online pharmacy. Strong sales resulted in Eroxon® ranking third on Navamedic’s most sold products in the Consumer Health segment in the first quarter of 2024.

“Eroxon® is a fast, safe and easily available product developed to help men improve not only their sexual health but also their quality of life. We hope for a similar response in Sweden as in the UK and Norway. Over time, we see greater growth potential in Sweden because Eroxon® will be the only non-prescription treatment for erectile dysfunction in the market,” says Jack Spira, Medical Director at Navamedic.

Four out of ten men in Sweden have experienced erectile dysfunction at some point, according to a new survey conducted on behalf of Navamedic. Medication is the most common measure, but the vast majority do not seek any help at all1.

Eroxon® offers a range of features which distinguishes it from other treatments of erectile dysfunction. First and foremost, it is an effective and fast-acting gel which typically helps men get an erection within ten minutes. It has a very good safety profile due to local effect with no systemic absorption. Eroxon® is approved as a treatment for erectile dysfunction in the EU and the US.

1 Survey conducted in Sweden by Novus 28 March – 11 April 2024.

For further information, please contact:
Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: [email protected]

Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: [email protected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/navamedic-asa/r/navamedic-asa–broad-launch-for-eroxon–in-sweden-today,c3973679

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/navamedic-asa-broad-launch-for-eroxon-in-sweden-today-302136644.html